Skip to main content
Clinical Trials/ACTRN12610000118000
ACTRN12610000118000
Completed
N/A

In treating patients with Critical Limb Ischaemia (CLI) using Hypertensive Extracorporeal Limb Perfusion(HELP) when compared to conventional treatments the study evaluates Safety and Efficacy via a multicentre, controlled trial.

Advanced Surgical Design and Manufacture0 sites40 target enrollmentFebruary 4, 2010

Overview

Phase
N/A
Intervention
Not specified
Conditions
Not specified
Sponsor
Advanced Surgical Design and Manufacture
Enrollment
40
Status
Completed
Last Updated
6 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
February 4, 2010
End Date
TBD
Last Updated
6 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Advanced Surgical Design and Manufacture

Eligibility Criteria

Inclusion Criteria

  • 1\) Only alternative treatment is imminent (within 8 weeks) major limb amputation
  • 2\) At least two vascular surgeons must agree that the treatment is the only remaining option for the patients
  • 3\) Patients must be over 18 years of age
  • 4\) Patients have critical limb ischaemia
  • 5\) Patients must be able to understand the risks and benefits of the trial and give written informed consent to participate
  • 6\) Patients must be fit for anaesthesia
  • 7\) Patients must have suitable anatomy determined by pre\-operative imaging and physical examination

Exclusion Criteria

  • 1\) Patients must not be in a concurrent clinical trial
  • 2\) Patient must not have compartment syndrome
  • 3\) Patients must not have an active systemic infection
  • 4\) Patient must not have serum abnormalities or high Creatine Phosphokinase (CPK) (greater than 3x the upper limit of normal for the testing laboratory) as deemed by the clinical investigator
  • 5\) Patients must not have general advanced debilitation or intercurrent organ failure
  • 6\) Patients must not have a serious wound infection (for example, Methicillin\-resistant Staphylococcus aureus (MRSA) of the ulcer) that in the opinion of the Clinical Investigator may impede the response to treatment
  • 7\) Patients must not have disseminated intravascular coagulation (DIC) as deemed by the clinical investigator

Outcomes

Primary Outcomes

Not specified

Similar Trials